Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol use disorder (AUD).
According to Clearmind, this milestone marks the first time a patient has received the company’s innovative treatment in a clinical setting—a critical step toward the development of a potential new therapy for millions affected by AUD worldwide.
In a statement, Dr. Adi Zuloff-Shani, PhD, CEO of Clearmind, remarked, “Dosing the first participant with CMND-100 in our study marks a landmark achievement towards the development of a new solution and offering new hope for the massive, underserved community suffering from alcoholism. This exciting event marks the first time our proprietary neuroplastogen compound has been given to humans under controlled clinical trial settings, bringing us closer to potentially delivering a revolutionary treatment for the millions of individuals and families suffering from AUD.”
The Phase 1/2a clinical trial is a multinational, multicenter, single- and multiple-dose study designed to establish the safety and optimal dosing of CMND-100. The trial will also assess early signals of efficacy, including reductions in alcohol consumption and cravings, which could pave the way for further development of this groundbreaking therapy.
